Neulasta and Rales - a phase IV clinical study of FDA data

Summary:

Rales is reported as a side effect among people who take Neulasta (pegfilgrastim), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Rituxan, and have Burkitt lymphoma.

The phase IV clinical study analyzes which people have Rales when taking Neulasta. It is created by eHealthMe based on reports of 92,148 people who have side effects when taking Neulasta from the FDA, and is updated regularly.

What is Neulasta?

Neulasta has active ingredients of pegfilgrastim. It is often used in agranulocytosis. eHealthMe is studying from 92,286 Neulasta users. Check the latest studies of Neulasta.

What is Rales?

Rales (an abnormal respiratory sound characterized by fine crackles) is found to be associated with 894 drugs and 949 conditions by eHealthMe. Check the latest studies of Rales.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

92,148 people reported to have side effects when taking Neulasta.
Among them, 12 people (0.01%) have Rales.

Among these 12 people:

How long have people been on Neulasta when they have Rales? *

What is the gender of people who have Rales when taking Neulasta? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Rales when taking Neulasta? *

What are other drugs people take besides Neulasta? *

What are other side effects people have besides Rales? *

Dyspnea (difficult or laboured breathing): 7 people, 58.33%
Febrile Neutropenia (fever with reduced white blood cells): 6 people, 50.00%
Fever: 5 people, 41.67%
Hypotension (abnormally low blood pressure): 4 people, 33.33%
Cough: 4 people, 33.33%
Dehydration (dryness resulting from the removal of water): 4 people, 33.33%
Diarrhea: 4 people, 33.33%
Drug Ineffective: 4 people, 33.33%
Oral Candidiasis (fungal infection of mouth): 4 people, 33.33%
Fall: 4 people, 33.33%

What are the existing conditions these people have? *

Renal Cancer Metastatic (cancer of kidney spreads to other part): 1 person, 8.33%
Rectal Cancer Metastatic (cancer of rectum spreads to other): 1 person, 8.33%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 8.33%
Neoplasm Malignant (cancer tumour): 1 person, 8.33%
Malignant Lymphoid Neoplasm (malignant growth or tumour caused by abnormal and uncontrolled cell division in lymph node): 1 person, 8.33%
Lymphoma (cancer that begins in immune system cells): 1 person, 8.33%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 8.33%
Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Neulasta and have Rales?

- Check whether Rales is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Neulasta:

Neulasta (92,286 reports)

Rales treatments and more:

Rales (9,085 reports)

Browse all side effects of Neulasta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rales:

Rales (894 drugs)

Browse all the conditions that are associated with Rales:

Rales (949 conditions)

Related publications that referenced our studies

Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .
Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on pegfilgrastim (the active ingredients of Neulasta) and Neulasta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.